Bone mineral density of patients with thalassemia major: Four-year follow-up
Bone mineral density of patients with thalassemia major: Four-year follow-up
复制标题
DOI：
10.1007/s002239900637
复制
发表时间：
1999-06-01
影响因子：
4.2
通讯作者：
Vainas, I
中科院分区：
文献类型：
--
作者：
Molyvda-Athanasopoulou, E;Sioundas, A;Vainas, I
本研究旨在评估50例9~28岁重型地中海贫血患者的骨密度(BMD)，并对其进行4年随访。他们在腰椎和股骨区域用DPX密度计测量，并分成三组：青春期前、青少年和成年人。所有患者都接受了钙和维生素D补充，50名患者中有8名接受了激素替代疗法(HRT)。与健康受试者相比，所有患者的骨密度均显著降低。三组腰椎骨密度平均值分别比同龄健康受试者低1.3、2、3个标准差。在研究期间，所有性腺功能正常的青少年患者和接受激素替代治疗的青少年患者的骨密度都有所增加。成人：随着治疗时间的延长，患者的骨密度也会增加。然而，患有低促性腺激素减退症但不能接受治疗的青少年和成年患者表现出骨密度的下降。重型地中海贫血患者的骨密度有较好的骨状态指标，应予以评价，尤其是对治疗的判定和随访有重要意义。
The purpose of this study was to evaluate the bone mineral density (BMD) of 50 patients aged 9-28 years, with thalassemia major and to assess the alterations of bone density in a 4-year follow-up study. They were measured with a DPX densitometer at the lumbar spine and femur area and divided into three groups: preadolescents, adolescents, and adults. All patients received calcium and vitamin D supplements, and 8 of the 50 received hormone replacement therapy (HRT). All patients had a significantly lower BMD compared with healthy subjects. Mean values of lumbar BMD of the three groups were 1.3, 2, and 3 standard deviations (SDs) lower than those of healthy subjects of the same age. All adolescent patients with normal gonadal function and those who received HRT showed an increase in BMD during the period of the study. Adult:patients also showed an increase in bone density as long as the treatment lasted. However, adolescent and adult patients who had hypogonadotropic hypogonadism but could not get therapy showed a decrease in bone density. BMD of patients with thalassemia major shows a good index of bone status which should be evaluated, especially for the determination and follow-up of therapy.